The Anti-CD274 (PD-L1) Antibody Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Anti-CD274 (PD-L1) Antibody Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Anti-CD274 (PD-L1) Antibody Market.

Some of the key takeaways from the Anti-CD274 (PD-L1) Antibody Pipeline Report:

• Companies across the globe are diligently working toward developing novel Anti-CD274 (PD-L1) Antibody treatment therapies with a considerable amount of success over the years. 
• Anti-CD274 (PD-L1) Antibody companies working in the treatment market are Curis, Compass Therapeutics, RemeGen, ABL Bio, SystImmune Inc., Incyte Corporation, Biotheus, Checkpoint Therapeutics, Jiangsu Hengrui Medicine, Chia Tai Tianqing Pharmaceuticala, CytomX Therapeutics, Effector Therapeutics, Jubilant Therapeutics, ChemoCentryx, Sorrento Therapeutics, Genor Biopharma, BeiGene, and others, are developing therapies for the Anti-CD274 (PD-L1) Antibody treatment 

• Emerging Anti-CD274 (PD-L1) Antibody therapies in the different phases of clinical trials are- CA 327, CTX-8371, RC 98, ABL501, GNC-035, INCB086550, PM 8001, Cosibelimab, SHR 1701, TQB 2450, CX-072, Tomivosertib, Research program: programmed cell death 1 ligand 1 inhibitor, CCX 559, Socazolimab, GB226, BGB-A333, and others are expected to have a significant impact on the Anti-CD274 (PD-L1) Antibody market in the coming years.   
• In August 2022, Chia Tai Tianqing Pharmaceutical Group has commenced a Phase II clinical trial to assess the effectiveness and safety of TQB2450 Injection when combined with chemotherapy with or without Anlotinib Hydrochloride Capsules for the initial treatment of individuals diagnosed with advanced endometrial cancer. Currently, the trial involves 69 participants and is projected to conclude by June 2024.
• In January 2022, Chia Tai Tianqing Pharmaceutical Group has launched a Phase III clinical trial, which is randomized and open-label, featuring a parallel controlled design. This study aims to compare the effectiveness and safety of TQB2450 when used alongside platinum-containing chemotherapy followed by TQB2450 in combination with Anlotinib against tislelizumab used with platinum-containing chemotherapy followed by tislelizumab in individuals with locally advanced (stage ⅢB/ⅢC), metastatic, or recurrent (Stage IV) non-squamous NSCLC cancer. Currently, the trial involves 390 participants and is expected to conclude by December 2023.

Anti-CD274 (PD-L1) Antibody Overview

Programmed death ligand 1 (PD-L1) and its counterpart PD-L2 are surface proteins typically found in normal tissues, serving to regulate T-cell function and prevent autoimmune reactions. In cases of tumors, PD-L1 is frequently overexpressed on the surface of cancer cells. It binds to programmed death 1 (PD-1) found on immune cells within the tumor, leading to a suppression of T-cell activity. This mechanism contributes to immune evasion and is one among several methods employed by tumors to avoid immune system detection and attack.

Get a Free Sample PDF Report to know more about Anti-CD274 (PD-L1) Antibody Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/anti-cd274-pd-l1-antibody-pipeline-insight

Emerging Anti-CD274 (PD-L1) Antibody Drugs Under Different Phases of Clinical Development Include:

• CA 327: Curis
• CTX-8371: Compass Therapeutics
• RC 98: RemeGen
• ABL501: ABL Bio
• GNC-035: SystImmune Inc.
• INCB086550: Incyte Corporation
• PM 8001: Biotheus
• Cosibelimab: Checkpoint Therapeutics
• SHR 1701: Jiangsu Hengrui Medicine
• TQB 2450: Chia Tai Tianqing Pharmaceuticala
• CX-072: CytomX Therapeutics
• Tomivosertib: Effector Therapeutics
• Research program: programmed cell death 1 ligand 1 inhibitor: Jubilant Therapeutics
• CCX 559: ChemoCentryx
• Socazolimab: Sorrento Therapeutics
• GB226: Genor Biopharma
• BGB-A333: BeiGene

Anti-CD274 (PD-L1) Antibody Pipeline Therapeutics Assessment

• Anti-CD274 (PD-L1) Antibody Assessment by Product Type
• Anti-CD274 (PD-L1) Antibody By Stage and Product Type
• Anti-CD274 (PD-L1) Antibody Assessment by Route of Administration
• Anti-CD274 (PD-L1) Antibody By Stage and Route of Administration
• Anti-CD274 (PD-L1) Antibody Assessment by Molecule Type
• Anti-CD274 (PD-L1) Antibody by Stage and Molecule Type

DelveInsight’s Anti-CD274 (PD-L1) Antibody Report covers around products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Anti-CD274 (PD-L1) Antibody product details are provided in the report. Download the Anti-CD274 (PD-L1) Antibody pipeline report to learn more about the emerging Anti-CD274 (PD-L1) Antibody therapies

Some of the key companies in the Anti-CD274 (PD-L1) Antibody Therapeutics Market include:

Key companies developing therapies for Anti-CD274 (PD-L1) Antibody are – CStone Pharmaceuticals, Celgene, Checkpoint Therapeutics, Alphamab Oncology, Eli Lilly and Company, Novartis Pharmaceuticals, Aurigene Discovery Technologies, Arbutus Biopharma, Compass Therapeutics, Curis, Biotheus, RemeGen, Incyte Corporation, Jubilant Therapeutics, ChemoCentryx, ABL Bio, Chia Tai Tianqing Pharmaceutical, Jiangsu Hengrui Medicine, Sorrento Therapeutics, CytomX Therapeutics, Genmab A/S, Secarna Pharmaceuticals, Avacta Life Sciences Limited, Fate Therapeutics, Hanmi Pharm.Co., Ltd., Celldex Therapeutics, Bolt Biotherapeutics, Bio-Thera Solutions, Acepodia Inc., Janux Therapeutics, Coherus Biosciences, Effector Therapeutics, Palleon Pharmaceuticals, F-star Therapeutics, BeiGene, and others.

Anti-CD274 (PD-L1) Antibody Pipeline Analysis:

The Anti-CD274 (PD-L1) Antibody pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Anti-CD274 (PD-L1) Antibody with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Anti-CD274 (PD-L1) Antibody Treatment.
• Anti-CD274 (PD-L1) Antibody key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Anti-CD274 (PD-L1) Antibody Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Anti-CD274 (PD-L1) Antibody market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Anti-CD274 (PD-L1) Antibody drugs and therapies

Anti-CD274 (PD-L1) Antibody Pipeline Market Drivers

• Rise in the global prevalence of various cancers, huge investment in the R&D activities, technological advancements and innovations are some of the important factors that are fueling the Anti-CD274 (PD-L1) Antibody Market.

Anti-CD274 (PD-L1) Antibody Pipeline Market Barriers

• However, adverse reactions induced by PD-L1 inhibitors such as immune-related adverse reactions (irAEs) and infusion-related reactions, high development costs can lead to high prices of the drug in the market and other factors are creating obstacles in the Anti-CD274 (PD-L1) Antibody Market growth. 

Scope of Anti-CD274 (PD-L1) Antibody Pipeline Drug Insight    

• Coverage: Global
• Key Anti-CD274 (PD-L1) Antibody Companies: Curis, Compass Therapeutics, RemeGen, ABL Bio, SystImmune Inc., Incyte Corporation, Biotheus, Checkpoint Therapeutics, Jiangsu Hengrui Medicine, Chia Tai Tianqing Pharmaceuticala, CytomX Therapeutics, Effector Therapeutics, Jubilant Therapeutics, ChemoCentryx, Sorrento Therapeutics, Genor Biopharma, BeiGene, and others
• Key Anti-CD274 (PD-L1) Antibody Therapies: CA 327, CTX-8371, RC 98, ABL501, GNC-035, INCB086550, PM 8001, Cosibelimab, SHR 1701, TQB 2450, CX-072, Tomivosertib, Research program: programmed cell death 1 ligand 1 inhibitor, CCX 559, Socazolimab, GB226, BGB-A333, and others
• Anti-CD274 (PD-L1) Antibody Therapeutic Assessment: Anti-CD274 (PD-L1) Antibody current marketed and Anti-CD274 (PD-L1) Antibody emerging therapies
• Anti-CD274 (PD-L1) Antibody Market Dynamics: Anti-CD274 (PD-L1) Antibody market drivers and Anti-CD274 (PD-L1) Antibody market barriers 

Request for Sample PDF Report for Anti-CD274 (PD-L1) Antibody Pipeline Assessment and clinical trials

Table of Contents

1. Anti-CD274 (PD-L1) Antibody Report Introduction

2. Anti-CD274 (PD-L1) Antibody Executive Summary

3. Anti-CD274 (PD-L1) Antibody Overview

4. Anti-CD274 (PD-L1) Antibody- Analytical Perspective In-depth Commercial Assessment

5. Anti-CD274 (PD-L1) Antibody Pipeline Therapeutics

6. Anti-CD274 (PD-L1) Antibody Late Stage Products (Phase II/III)

7. Anti-CD274 (PD-L1) Antibody Mid Stage Products (Phase II)

8. Anti-CD274 (PD-L1) Antibody Early Stage Products (Phase I)

9. Anti-CD274 (PD-L1) Antibody Preclinical Stage Products

10. Anti-CD274 (PD-L1) Antibody Therapeutics Assessment

11. Anti-CD274 (PD-L1) Antibody Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Anti-CD274 (PD-L1) Antibody Key Companies

14. Anti-CD274 (PD-L1) Antibody Key Products

15. Anti-CD274 (PD-L1) Antibody Unmet Needs

16 . Anti-CD274 (PD-L1) Antibody Market Drivers and Barriers

17. Anti-CD274 (PD-L1) Antibody Future Perspectives and Conclusion

18. Anti-CD274 (PD-L1) Antibody Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services